查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718063

大腸直腸癌篩檢和診斷市場（按類型、產品、應用和最終用戶分類）—2025 年至 2030 年全球預測

Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年大腸直腸癌篩檢和診斷市值將達18.6億美元，2025年將達19.9億美元，複合年成長率為7.41%，到2030年將達28.6億美元。

主要市場統計數據
基準年2024年 18.6億美元
預計2025年 19.9億美元
預測年份 2030 28.6億美元
複合年成長率（%） 7.41%

大腸直腸癌仍然是全球最重大的健康挑戰之一，近年來其篩檢和診斷過程迅速發展。本執行摘要說明探討了這個充滿活力的行業變革的促進因素，包括技術進步、不斷變化的市場趨勢和不斷變化的消費者需求。整體而言，診斷方法不斷創新，篩檢通訊協定不斷改進，並且越來越重視早期檢測和個人化醫療。這些發展不僅延長了壽命，而且重塑了我們的疾病管理和治療方法。

本書的目標讀者是決策者、行業專家、醫療保健專業人士以及任何想要更好地了解市場如何轉型的人士。該摘要將詳細的見解與可行的建議相結合，提供了權威的觀點，說明哪些因素正在推動變革，以及行業相關人員和醫療保健提供者應該考慮哪些策略方向。每個部分都基於對當前實踐、市場細分、區域趨勢和競爭格局的全面回顧，以描繪出這個複雜行業的整體情況。

重新定義大腸直腸癌篩檢和診斷的變革性轉變

大腸直腸癌篩檢和診斷市場正在經歷一場由尖端技術的整合和臨床實踐的不斷發展所推動的變革。影像和血液篩檢的創新重新定義了早期檢測。新的協議正在取代傳統方法，提供患者友善的解決方案，以提高精確度並減少不適和手術風險。這一顯著進步得益於嚴格的監管措施、增加的研究資金以及全球對預防性醫療保健策略的推動。

技術突破正在顛覆傳統範式。例如，診斷影像技術的改進現在可以提供更高的解析度和洞察力，使臨床醫生能夠檢測到以前可能被忽視的細微變化。同樣，血液檢測的進步提供了更準確的生物標記物，為早期療育打開了大門。這種轉變得益於一系列診斷設備和耗材的引入，這些設備和耗材顯著縮短了周轉時間，並加快了病人歷程從篩檢到治療的進程。

此外，患者意識的不斷提高和公共衛生宣傳活動的不斷發展也進一步支持了這一發展。隨著大眾對早期檢測的好處的了解越來越多，對創新篩檢測試和診斷解決方案的需求也越來越大。這種技術、監管和社會變革的結合不僅僅是漸進的，而且具有變革性，它重新定義了整個市場格局，並預示著未來結腸直腸癌的治療將以前所未有的精確度和護理度進行。

更深入的市場區隔與分析

對市場的深入研究揭示了清晰的細分見解，為快速轉型提供了明確的方向。根據類型，市場可分為篩檢測試和糞便檢驗。篩檢測試細分為血液測試和創新影像檢查。特別是影像檢查已發展成為大腸鏡檢查、CT結腸造影和軟性乙狀結腸鏡檢查等專門的檢查方式，每種方式在早期檢測和詳細的解剖視覺化方面都具有獨特的優勢。同時，糞便檢驗已發展出糞便免疫化學檢查、癒創木脂大便潛血試驗和多目標糞便DNA檢測等方法，每種方法都顯示出其獨特的診斷準確性和患者便利性。

從產品角度來看，市場明顯分為消耗品和設備。消耗品包括套件和試劑，在確保診斷通訊協定的無縫運作中發揮至關重要的作用。同時，設備類別包括CT掃描器和內視鏡等技術，強調高精度設備和先進的診斷能力。這種細分強調了增強測試可重複性的耗材與提供高度診斷準確性的高階設備之間的平衡。

當考慮應用程式段時，它會進一步細分。市場分為疾病監測、早期檢測和預後評估，反映了及時介入和持續患者管理的策略重點。這些應用顯示了病人歷程的每一步，從初步篩檢到持續管理，如何依賴精密工具和強大的診斷支援。

最後，基於最終用戶的細分為市場營運動態提供了關鍵見解。對門診手術中心、診斷實驗室、醫院和研究機構的調查顯示，對先進的診斷和篩檢解決方案有廣泛的需求。每個最終用戶群體都有自己的營運要求，醫院和診斷實驗室因其在患者照護中的核心作用而引領市場。此外，門診手術中心和研究機構由於提供專業知識和推動創新而變得越來越重要。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球大腸直腸癌發生率上升
      • 預防性醫療保健和患者早期發現的重要性日益增加
      • 政府對國家癌症篩檢計劃和指南的承諾和資助
    • 限制因素
      • 與大腸癌篩檢相關的心理不適和恥辱感
    • 機會
      • 全球對數位健康工具的投資激增
      • 整合人工智慧提高大腸直腸癌診斷的準確性
    • 任務
      • 大腸癌篩檢工具監理核准延遲
  • 市場區隔分析
    • 類型：影像檢查因其診斷和治療能力而越來越受到青睞。
    • 應用：透過擴大結直腸癌篩檢和診斷的使用來實現癌症的早期發現
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 大腸癌篩檢和診斷市場（按類型）

  • 篩檢測試
    • 血液檢查
    • 影像檢查
      • 大腸鏡檢查
      • CT大腸造影
      • 軟性乙狀結腸鏡檢查
  • 糞便檢驗
    • 大便潛血試驗
    • 癒創木酚法糞便大便潛血試驗
    • 多目標糞便DNA檢測

7. 大腸癌篩檢和診斷市場（按產品）

  • 耗材
    • 套件
    • 試劑
  • 裝置
    • CT掃描儀
    • 內視鏡檢查

8. 大腸直腸癌篩檢和診斷市場（按應用）

  • 疾病監測
  • 早期檢測
  • 預後評估

9. 大腸直腸癌篩檢和診斷市場（按最終用戶）

  • 門診手術中心
  • 診斷實驗室
  • 醫院
  • 研究機構

10.美洲大腸直腸癌篩檢與診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區大腸直腸癌篩檢與診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲的大腸癌篩檢和診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • KARL STORZ SE & Co. KG
  • Medtronic PLC
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Novigenix SA
  • Olympus Corporation
  • Prenetics Global Limited
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AF41

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 1.86 billion in 2024 and is projected to grow to USD 1.99 billion in 2025, with a CAGR of 7.41%, reaching USD 2.86 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.86 billion
Estimated Year [2025] USD 1.99 billion
Forecast Year [2030] USD 2.86 billion
CAGR (%) 7.41%

Colorectal cancer remains one of the most significant health challenges worldwide, and its screening and diagnostic processes have undergone rapid evolution in recent years. This executive summary provides a detailed look into the drivers of change in this dynamic field, including advancements in technology, shifting market trends, and evolving consumer demands. The overall landscape is marked by innovative diagnostic methods, improved screening protocols, and a deepened focus on early detection and personalized care. These developments are not only extending lives but also reshaping the approach to disease management and treatment.

The narrative that follows is designed for decision-makers, industry experts, and healthcare professionals who require a nuanced understanding of how the market is transforming. By weaving together detailed insights with actionable recommendations, this summary offers an authoritative perspective on what factors are fueling change and what strategic directions both industry stakeholders and healthcare providers should consider. Each section builds on a comprehensive review of current practices, market segmentation, regional trends, and the competitive environment to paint a holistic picture of this complex industry.

Transformative Shifts Redefining Colorectal Cancer Screening and Diagnostics

The colorectal cancer screening and diagnostic market is witnessing transformative shifts driven by the integration of advanced technology and the continuous evolution of clinical practices. Innovations in imaging and blood-based screening have redefined early detection techniques. New protocols are rapidly replacing traditional methods, offering enhanced accuracy and patient-friendly solutions that reduce discomfort and procedural risks. This remarkable progression is bolstered by stringent regulatory measures, increased research funding, and a global push towards more preventive healthcare strategies.

Technological breakthroughs are disrupting conventional paradigms. For example, enhanced imaging techniques now provide greater resolution and insight, giving clinicians the ability to detect subtle changes that were previously missed. Similarly, advancements in blood tests have led to more accurate biomarkers, opening doors to earlier interventions. These shifts are supported by the introduction of a range of diagnostic instruments and consumables that significantly reduce turnaround times, thereby accelerating the patient journey from screening to treatment.

In addition, evolving patient awareness and increasing public health campaigns have further catalyzed these developments. As populations become more informed about the benefits of early detection, the demand for innovative screening tests and diagnostic solutions is on the rise. This combination of technological, regulatory, and societal changes is not merely incremental but transformative, redefining the overall market landscape and promising a future where colorectal cancer is managed with unprecedented precision and care.

Deep Dive into Market Segmentation and Analysis

A meticulous examination of the market uncovers distinct segmentation insights that offer clarity and direction amid rapid transformation. When considering the market under the lens of type, the landscape is divided into an array of screening tests and stool tests. The screening tests segment itself is nuanced by further subdivisions into blood tests and innovative imaging tests. Particularly, imaging tests have evolved into specialized modalities including colonoscopy, CT colonography, and flexible sigmoidoscopy - each offering unique advantages in early detection and detailed anatomical visualization. On the other hand, stool tests have evolved to include methods such as the fecal immunochemical test, guaiac-based fecal occult blood test, and multitarget stool DNA testing, each demonstrating distinct diagnostic accuracy and patient convenience.

When viewed through the prism of products, the market is clearly delineated into consumables and instruments. Consumables, which include both kits and reagents, play a critical role in ensuring the seamless operation of diagnostic protocols, while the instrument segment, encompassing technologies such as CT scanners and endoscopes, highlights the emphasis on high-precision equipment and advanced diagnostic capabilities. This formation of segmentation underscores the balance between consumable supplies that drive the repeatability of tests and high-end instruments which offer advanced diagnostic accuracy.

Further granularity is achieved when the application segment is considered. The market is segmented into disease monitoring, early detection, and prognosis assessment, reflecting a strategic emphasis on timely interventions and continuous patient management. These applications illustrate how each stage of the patient's journey-from initial screening to ongoing management-relies on precision tools and robust diagnostic support.

Finally, the segmentation based on end user provides critical insights into the operational dynamics of the market. With the market studied across ambulatory surgical centers, diagnostics laboratories, hospitals, and research institutes, it is evident that the demand for advanced diagnostic and screening solutions is pervasive. Each end user segment has unique operational requirements, with hospitals and diagnostic laboratories leading the charge due to their central role in patient care. Ambulatory surgical centers and research institutes are also gaining increased attention as they contribute specialized expertise and drive innovation.

Based on Type, market is studied across Screening Tests and Stool Tests. The Screening Tests is further studied across Blood Tests and Imaging Tests. The Imaging Tests is further studied across Colonoscopy, CT Colonography, and Flexible Sigmoidoscopy. The Stool Tests is further studied across Fecal Immunochemical Test, Guaiac-Based Fecal Occult Blood Test, and Multitarget Stool DNA Testing.

Based on Product, market is studied across Consumables and Instruments. The Consumables is further studied across Kits and Reagents. The Instruments is further studied across CT Scanners and Endoscopes.

Based on Application, market is studied across Disease Monitoring, Early Detection, and Prognosis Assessment.

Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostics Laboratories, Hospitals, and Research Institutes.

Regional Trends Shaping the Diagnostic Landscape

Understanding the market's regional dynamics is essential to capturing the breadth of change occurring in colorectal cancer screening and diagnostics. In the Americas, rapid technological adoption and a proactive approach to health policy have created an environment where advanced diagnostic techniques are quickly integrated into clinical practice. Health systems in this region are increasingly investing in state-of-the-art screening procedures that emphasize early detection and improved patient outcomes.

In the region encompassing Europe, the Middle East, and Africa, there is a confluence of historically strong healthcare frameworks with an increasing appetite for innovation. Enhanced investment in research and development, along with robust regulatory support, nudges the market towards a more conservative yet steady adoption of new technologies. Differing economic landscapes and healthcare policies drive specific localized strategies that cater effectively to patient demographics and disease prevalence patterns.

The Asia-Pacific region, characterized by its rapid economic growth and expanding healthcare infrastructure, is emerging as a focal point for colorectal cancer diagnostics. Here, a growing middle class and increased government healthcare initiatives facilitate the widespread implementation of advanced screening tests and diagnostic instruments. This region sees a unique blend of traditional healthcare practices with modern diagnostic technologies, supporting a coherent strategy that addresses both early detection and ongoing disease management. Collectively, these regional insights illustrate how geographic nuances contribute to tailored market strategies and influence global investment decisions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Company Insights Influencing Market Evolution

The competitive landscape of colorectal cancer diagnostics is driven by a host of companies that are at the forefront of medical innovation and technological differentiation. Market leaders such as Abbott Laboratories and AbbVie Inc. provide a strong foundation through diversified portfolio offerings, emphasizing reliability and clinical efficacy. Recognized giants like Agilent Technologies, Inc. and Bayer AG have innovated extensively in imaging and diagnostic reagents, setting high benchmarks for emerging players. Companies including Becton, Dickinson and Company and Bio-Rad Laboratories, Inc. have leveraged their widespread operational networks to drive faster diagnostics and improved screening solutions.

The role of organizations like bioMerieux SA and Bristol-Myers Squibb Company is increasingly significant, as their research-driven breakthroughs continue to influence diagnostic protocols. Clinical Genomics Technologies Pty Ltd. and Eiken Chemical Co., Ltd. introduce niche and specialized solutions that add depth to the diagnostic toolkit. The contributions from Epigenomics AG and Exact Sciences Corp. are noteworthy; these companies are instrumental in transforming early detection strategies with a focus on genetic and molecular indicators.

Global leaders such as F. Hoffmann-La Roche Ltd. and Fujifilm Holdings Corporation have made notable advances with imaging solutions and broader diagnostic applications. GE HealthCare Technologies, Inc., along with Guardant Health, Inc., have expanded the frontier of precision diagnostics through a combination of advanced equipment and innovative screening methodologies. Hologic, Inc., Illumina, Inc., and KARL STORZ SE & Co. KG further consolidate the competitive landscape with their continued advancements in endoscopic and genomics-based technologies. Additionally, Medtronic PLC and Merck KGaA commit substantial resources to integrate diagnostic instruments into broader clinical pathways.

Not to be overlooked, companies like Myriad Genetics, Inc. and Novartis AG stand out for their research and personalized medicine approaches, while emerging players such as Novigenix SA and Olympus Corporation offer disruptive solutions that challenge existing paradigms. The industry is further enriched by contributions from Prenetics Global Limited and QIAGEN N.V., whose precision-based tools are instrumental in refining diagnostic accuracy. Quest Diagnostics Incorporated, Sanofi SA, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. round out this dynamic ecosystem, ensuring that innovation, quality, and efficacy remain at the heart of new product development and market expansion.

The report delves into recent significant developments in the Colorectal Cancer Screening & Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Clinical Genomics Technologies Pty Ltd., Eiken Chemical Co., Ltd., Epigenomics AG, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Guardant Health, Inc., Hologic, Inc., Illumina, Inc., KARL STORZ SE & Co. KG, Medtronic PLC, Merck KGaA, Myriad Genetics, Inc., Novartis AG, Novigenix SA, Olympus Corporation, Prenetics Global Limited, QIAGEN N.V., Quest Diagnostics Incorporated, Sanofi SA, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.. Strategic Recommendations for Industry Players to Drive Future Growth

To navigate the rapidly evolving landscape, industry leaders must adopt a proactive approach that blends innovation with strategic investments. First, fostering robust research collaborations across academic and clinical institutions can accelerate the development of next-generation diagnostic technologies. Investment in digital transformation, including the integration of artificial intelligence and machine learning, is crucial in enhancing the speed and accuracy of diagnostic tools. These investments not only improve patient outcomes but also serve as a catalyst for operational efficiency throughout the healthcare continuum.

Leveraging real-world data and fostering a feedback loop between clinical practices and research becomes paramount. By engaging closely with end users such as hospitals, diagnostics laboratories, and ambulatory surgical centers, companies can develop products that directly respond to clinical needs and improve overall diagnostic accuracy. Furthermore, tailoring product development to regional specifics in the Americas, Europe, Middle East & Africa, and Asia-Pacific ensures that innovations are both cost-effective and aligned with local healthcare dynamics.

Industry players are encouraged to pursue strategic alliances and mergers that can bridge gaps between diagnostic consumables and advanced imaging instruments. A balanced portfolio that caters to both consumables and high-end instruments is essential to capture the full market potential. This approach involves continuously updating existing product lines, pursuing regulatory approvals for novel technologies, and exploring innovative reimbursement models that incentivize early detection and disease management.

In parallel, expanding market presence through targeted regional strategies will ensure a broader reach and improved market penetration. Emphasizing patient-centric approaches that incorporate wellness programs, preventive care initiatives, and community outreach can further solidify a company's brand reputation while creating sustainable revenue streams. A forward-thinking strategic roadmap involving digital innovation, enhanced clinical partnerships, and regional customization will enable industry leaders to maintain their competitive edge in the evolving diagnostic landscape.

Summative Conclusions on the Evolving Diagnostic Paradigm

The analytical journey through the colorectal cancer screening and diagnostic field highlights a rapidly evolving landscape defined by significant technological advancements, shifting market dynamics, and heightened competitive fervor. Significant progress in screening and diagnostic methodologies, from advanced imaging tests to innovative stool tests, underscores the market's response to the escalating demand for early detection and continuous disease monitoring. The segmentation analysis further reveals a complex matrix where types, products, applications, and end users play interdependent roles in shaping market strategies.

Regional variations contribute unique challenges and opportunities, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each offering distinct pathways for growth and innovation. This diversity in regional profiles not only demands tailored approaches but also encourages cross-market synergies that could drive future advancements in diagnostic technology.

The competitive landscape, marked by industry behemoths alongside nimble innovators, reflects an ecosystem built on continuous improvement and collaborative initiatives. Together, these insights underscore the need for a dual focus on technology and strategy. The sector must dynamically embrace change while rigorously balancing clinical efficacy with market expansion strategies. Ultimately, the integration of advanced diagnostic tools with strategic partnerships is key to paving the way for a future where colorectal cancer is detected with greater precision and managed more effectively.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of colorectal cancer cases worldwide
      • 5.1.1.2. Growing emphasis on preventive healthcare and early detection among patients
      • 5.1.1.3. Government initiatives and funding support for national cancer screening programs and guidelines
    • 5.1.2. Restraints
      • 5.1.2.1. Psychological discomfort and stigma associated with colorectal cancer screening procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in investments in digital health tools worldwide
      • 5.1.3.2. Integration of artificial intelligence for enhanced accuracy in colorectal cancer diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Delayed regulatory approval procedures for colorectal cancer screening tools
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing preference for imaging tests due to its dual diagnostic and therapeutic capability
    • 5.2.2. Application: Expanding application of colorectal cancer screening and diagnostics for early cancer detection
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Colorectal Cancer Screening & Diagnostic Market, by Type

  • 6.1. Introduction
  • 6.2. Screening Tests
    • 6.2.1. Blood Tests
    • 6.2.2. Imaging Tests
      • 6.2.2.1. Colonoscopy
      • 6.2.2.2. CT Colonography
      • 6.2.2.3. Flexible Sigmoidoscopy
  • 6.3. Stool Tests
    • 6.3.1. Fecal Immunochemical Test
    • 6.3.2. Guaiac-Based Fecal Occult Blood Test
    • 6.3.3. Multitarget Stool DNA Testing

7. Colorectal Cancer Screening & Diagnostic Market, by Product

  • 7.1. Introduction
  • 7.2. Consumables
    • 7.2.1. Kits
    • 7.2.2. Reagents
  • 7.3. Instruments
    • 7.3.1. CT Scanners
    • 7.3.2. Endoscopes

8. Colorectal Cancer Screening & Diagnostic Market, by Application

  • 8.1. Introduction
  • 8.2. Disease Monitoring
  • 8.3. Early Detection
  • 8.4. Prognosis Assessment

9. Colorectal Cancer Screening & Diagnostic Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Diagnostics Laboratories
  • 9.4. Hospitals
  • 9.5. Research Institutes

10. Americas Colorectal Cancer Screening & Diagnostic Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Colorectal Cancer Screening & Diagnostic Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Colorectal Cancer Screening & Diagnostic Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. ColoWatch and Bracco Diagnostics partner to expand the availability of virtual colonoscopy for the early detection of colon and rectal cancer
    • 13.3.2. Owkin and Roche collaborate on MSIntuit CRC v2 to enhance colorectal cancer diagnosis through AI advancements
    • 13.3.3. FDA approval of Cologuard Plus enhances colorectal cancer screening with improved sensitivity and specificity
    • 13.3.4. FDA approval of Guardant Shield blood test enhances colorectal cancer screening with non-invasive option
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Agilent Technologies, Inc.
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. bioMerieux SA
  • 8. Bristol-Myers Squibb Company
  • 9. Clinical Genomics Technologies Pty Ltd.
  • 10. Eiken Chemical Co., Ltd.
  • 11. Epigenomics AG
  • 12. Exact Sciences Corp.
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fujifilm Holdings Corporation
  • 15. GE HealthCare Technologies, Inc.
  • 16. Guardant Health, Inc.
  • 17. Hologic, Inc.
  • 18. Illumina, Inc.
  • 19. KARL STORZ SE & Co. KG
  • 20. Medtronic PLC
  • 21. Merck KGaA
  • 22. Myriad Genetics, Inc.
  • 23. Novartis AG
  • 24. Novigenix SA
  • 25. Olympus Corporation
  • 26. Prenetics Global Limited
  • 27. QIAGEN N.V.
  • 28. Quest Diagnostics Incorporated
  • 29. Sanofi SA
  • 30. Siemens AG
  • 31. Sysmex Corporation
  • 32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET MULTI-CURRENCY
  • FIGURE 2. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET MULTI-LANGUAGE
  • FIGURE 3. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 4. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS COLOR